Suppr超能文献

吸入后最初30分钟内尿沙丁胺醇排泄的剂量-反应关系及可重复性。

Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation.

作者信息

Tomlinson H S, Corlett S A, Chrystyn H

机构信息

School of Pharmacy, University of Bradford, Bradford, BD7 1DP.

出版信息

Br J Clin Pharmacol. 2003 Aug;56(2):225-7. doi: 10.1046/j.1365-2125.2003.01864.x.

Abstract

AIMS

To determine the reproducibility and dose-response relationship for urinary salbutamol excretion post inhalation.

METHODS

Fifteen volunteers inhaled either one, two, three, four or five doses of 100 micro g salbutamol on separate days and then seven of these also repeated each of the one, three and five doses on five occasions. After each study dose urine was collected 30 min post inhalation.

RESULTS

The mean (SD) 30 min urinary salbutamol after one, two, three, four and five doses was 2.61 (1.0.), 5.47 (1.59), 8.68 (2.73), 12.34 (3.96) and 15.99 (4.50) micro g, respectively. Statistical analysis revealed a linear relationship (P < 0.001). Mean (SD) coefficient of variation after one, three and five doses was 10.5 (3.6), 10.1 (2.7) and 9.4 (2.3)%.

CONCLUSIONS

The 30 min salbutamol urinary excretion post inhalation pharmacokinetic method, to compare inhaled products, is linear with inhaled dose and reproducible.

摘要

目的

确定吸入后尿中沙丁胺醇排泄的可重复性及剂量反应关系。

方法

15名志愿者在不同日期分别吸入1、2、3、4或5剂100微克的沙丁胺醇,其中7名志愿者还对1、3和5剂分别重复吸入5次。每次研究剂量吸入后30分钟收集尿液。

结果

1、2、3、4和5剂后30分钟尿中沙丁胺醇的平均(标准差)分别为2.61(1.0)、5.47(1.59)、8.68(2.73)、12.34(3.96)和15.99(4.50)微克。统计分析显示呈线性关系(P<0.001)。1、3和5剂后的平均(标准差)变异系数分别为10.5(3.6)%、10.1(2.7)%和9.4(2.3)%。

结论

吸入后30分钟沙丁胺醇尿排泄药代动力学方法用于比较吸入产品时,与吸入剂量呈线性关系且具有可重复性。

相似文献

1
3
Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged.
Br J Clin Pharmacol. 2000 Sep;50(3):281-4. doi: 10.1046/j.1365-2125.2000.00255.x.
5
Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization.
Br J Clin Pharmacol. 2002 Aug;54(2):115-9. doi: 10.1046/j.1365-2125.2002.01632.x.
6
New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation.
J Pharm Biomed Anal. 2009 Sep 8;50(2):175-82. doi: 10.1016/j.jpba.2009.04.006. Epub 2009 Apr 11.
9
Inhaled salbutamol and doping control: effects of dose on urine concentrations.
Clin J Sport Med. 2008 May;18(3):282-5. doi: 10.1097/JSM.0b013e3181705c8c.
10
Volumatic usage: some generic salbutamol metered dose inhalers can be used.
Thorax. 1994 Nov;49(11):1162-3. doi: 10.1136/thx.49.11.1162.

引用本文的文献

1
The Bioavailability of Salbutamol in Urine via Volumatic and Nonvolumatic Valved Holding Chambers.
World Allergy Organ J. 2011 Nov;4(11):179-83. doi: 10.1097/WOX.0b013e31823890f6. Epub 2011 Nov 18.
2
Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?
Br J Clin Pharmacol. 2013 Jan;75(1):7-14. doi: 10.1111/j.1365-2125.2012.04323.x.
3
Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion.
Br J Clin Pharmacol. 2011 Apr;71(4):608-10. doi: 10.1111/j.1365-2125.2010.03873.x.

本文引用的文献

3
Methods to identify drug deposition in the lungs following inhalation.
Br J Clin Pharmacol. 2001 Apr;51(4):289-99. doi: 10.1046/j.1365-2125.2001.01304.x.
5
Effects of airway calibre on lung delivery of nebulised salbutamol.
Thorax. 1997 Dec;52(12):1036-9. doi: 10.1136/thx.52.12.1036.
8
Volumatic usage: some generic salbutamol metered dose inhalers can be used.
Thorax. 1994 Nov;49(11):1162-3. doi: 10.1136/thx.49.11.1162.
9
Determination of the relative bioavailability of salbutamol to the lung following inhalation.
Br J Clin Pharmacol. 1992 Oct;34(4):311-5. doi: 10.1111/j.1365-2125.1992.tb05921.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验